The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer

The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer

Although the standard treatment for ovarian carcinoma with peritoneal metastases is systemic chemotherapy alone or systemic chemotherapy with debulking surgery, a new technique gains more ground: a combination of hipertermic intraperitoneal chemotherapy (HIPEC) and optimal cytoreduction surgery. The...

Full description

Bibliographic Details
Main Authors: Lucian ALECU, Adrian TULIN, Iulian SLAVU, Cristina ORLOV-SLAVU, Bogdan SOCEA, Cornelia NITIPIR
Format: Article
Language:English
Published: Media Med Publicis 2020-12-01
Series:Modern Medicine
Subjects:
hipec
ovarian cancer
peritoneal metastasis
Online Access:https://medicinamoderna.ro/wp-content/uploads/2020/12/RMM_art-2.pdf
id doaj-3c57ae64933f42ff802d8c50ecdeea86
record_format Article
spelling doaj-3c57ae64933f42ff802d8c50ecdeea862021-06-02T16:24:06ZengMedia Med PublicisModern Medicine1223-04722360-24732020-12-01274261265https://doi.org/10.31689/rmm.2020.27.4.261The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian CancerLucian ALECU0Adrian TULIN1Iulian SLAVU2Cristina ORLOV-SLAVU3Bogdan SOCEA4https://orcid.org/0000-0003-2155-1808Cornelia NITIPIR5https://orcid.org/0000-0002-5985-3759Clinic of General Surgery, „Agrippa Ionescu” Emergency Hospital, Bucharest, RomaniaClinic of General Surgery, „Agrippa Ionescu” Emergency Hospital, Bucharest, RomaniaClinic of Oncology, Elias University Emergency Hospital, Bucharest, RomaniaClinic of Oncology, Elias University Emergency Hospital, Bucharest, RomaniaClinic of Surgery, „Sfantul Pantelimon” Emergency Hospital, Bucharest, RomaniaClinic of Oncology, Elias University Emergency Hospital, Bucharest, RomaniaAlthough the standard treatment for ovarian carcinoma with peritoneal metastases is systemic chemotherapy alone or systemic chemotherapy with debulking surgery, a new technique gains more ground: a combination of hipertermic intraperitoneal chemotherapy (HIPEC) and optimal cytoreduction surgery. The proof is mounting regarding the benefits of HIPEC for patients with metastatic ovarian carcinoma but it still lacks a standard protocol of use. It has increased costs, and incomplete data regarding its safety. Due to these reasons, it is still considered an alternative treatment. Our study aimed to evaluate the published literature regarding this technique from the point of view of safety and efficacy when compared with the standard of care treatment. https://medicinamoderna.ro/wp-content/uploads/2020/12/RMM_art-2.pdfhipecovarian cancerperitoneal metastasis
collection DOAJ
language English
format Article
sources DOAJ
author Lucian ALECU
Adrian TULIN
Iulian SLAVU
Cristina ORLOV-SLAVU
Bogdan SOCEA
Cornelia NITIPIR
spellingShingle Lucian ALECU
Adrian TULIN
Iulian SLAVU
Cristina ORLOV-SLAVU
Bogdan SOCEA
Cornelia NITIPIR
The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
Modern Medicine
hipec
ovarian cancer
peritoneal metastasis
author_facet Lucian ALECU
Adrian TULIN
Iulian SLAVU
Cristina ORLOV-SLAVU
Bogdan SOCEA
Cornelia NITIPIR
author_sort Lucian ALECU
title The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
title_short The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
title_full The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
title_fullStr The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
title_full_unstemmed The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
title_sort controversy of intraperitoneal hyperthermic chemotherapy for ovarian cancer
publisher Media Med Publicis
series Modern Medicine
issn 1223-0472
2360-2473
publishDate 2020-12-01
description Although the standard treatment for ovarian carcinoma with peritoneal metastases is systemic chemotherapy alone or systemic chemotherapy with debulking surgery, a new technique gains more ground: a combination of hipertermic intraperitoneal chemotherapy (HIPEC) and optimal cytoreduction surgery. The proof is mounting regarding the benefits of HIPEC for patients with metastatic ovarian carcinoma but it still lacks a standard protocol of use. It has increased costs, and incomplete data regarding its safety. Due to these reasons, it is still considered an alternative treatment. Our study aimed to evaluate the published literature regarding this technique from the point of view of safety and efficacy when compared with the standard of care treatment.
topic hipec
ovarian cancer
peritoneal metastasis
url https://medicinamoderna.ro/wp-content/uploads/2020/12/RMM_art-2.pdf
work_keys_str_mv AT lucianalecu thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT adriantulin thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT iulianslavu thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT cristinaorlovslavu thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT bogdansocea thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT cornelianitipir thecontroversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT lucianalecu controversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT adriantulin controversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT iulianslavu controversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT cristinaorlovslavu controversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT bogdansocea controversyofintraperitonealhyperthermicchemotherapyforovariancancer
AT cornelianitipir controversyofintraperitonealhyperthermicchemotherapyforovariancancer
_version_ 1721402849286422528

Similar Items